Background
==========

The prognostic factors of lung cancer might be important in daily clinical practice due to its high prevalence and mortality rates. In recent years, the efficacy of cancer treatment has achieved a qualitative leap since many oncogenic drivers have been discovered, such as anaplastic lymphoma kinase (ALK) genes, epidermal growth factor receptor (EGFR), and vascular endothelial growth factor (VEGF). These developments have improved molecular diagnosis and accurate therapy for lung cancer patients.

The ALK gene was first described as NPM-ALK fusion protein, mainly in anaplastic large-cell lymphomas \[[@b1-medscimonit-25-675]\]. It accounts for about 6.7% of NSCLCs \[[@b2-medscimonit-25-675]\] and 11% of lung adenocarcinoma \[[@b3-medscimonit-25-675]\]. Although a low proportion of lung cancer patients have ALK rearrangements, the total number of the cases is considerable and these patients would benefit from molecular-targeted treatment. Thus, it is important to explore predictive factors among lung cancer patients that harbor ALK rearrangements in clinical practice.

Serum tumor markers, including carcinoembryonic antigen (CEA) \[[@b4-medscimonit-25-675]\], squamous cell carcinoma antigen (SCCA) \[[@b5-medscimonit-25-675]\], cytokeratin-19 fragments (Cyfra21-1) \[[@b6-medscimonit-25-675]\], and neuron-specific enolase (NSE) \[[@b7-medscimonit-25-675]\], have been found to be useful biomarkers in lung cancer, but no consistent view has been reached yet. Indeed, the clinical significance of these serum tumor markers in ALK-positive lung adenocarcinoma have not been thoroughly investigated.

In this study, we carried out a retrospective clinical research of a total 574 operable lung adenocarcinoma patients in which 54 patients had ALK rearrangements. We covered clinical factors between serum tumor markers and the clinical features in patients of stage I, II, and III who underwent partial or complete surgical operation. We explored the clinical features in ALK-positive lung adenocarcinoma and assessed whether these serum tumor markers are independent indicators for prognosis in these patients.

Material and Methods
====================

Patient selection
-----------------

We retrospectively analyzed a database of consecutive lung adenocarcinoma patients treated by surgery between March 2011 and August 2016 at Tianjin Medical University Cancer Institute and Hospital. Approval by the Research Ethics Committee of Tianjin Medical University Cancer Institute was gained and its purpose was to explore the clinical significance of serum tumor markers at the beginning of diagnosis as prognostic factors in the subset of lung adenocarcinoma patients with ALK rearrangements. Examinations prior to the operation included physical examination, level of serum tumor biomarkers, blood chemistry analysis, CT scan, fiberoptic bronchoscopy, brain MRI, and bone scanning. All patients underwent partial or complete surgical resection exclusively. The selection criteria were as follows: (a) the pathological diagnosis was lung adenocarcinoma; (b) ALK-rearrangement positive (by the Ventana ALK \[D5F3\] IHC Kit, Roche, Switzerland); (c) clinical stages I, II, IIIA, or IIIB disease defined by the tumor node metastasis (TNM) criteria of NSCLC (AJCC,7th edition) and the TNM stage assessment was according to CT scans, brain MRI, and bone emission CT scans; (d) patients were untreated at the time routine blood analyses were performed; and (e) preoperative evaluation showed that surgery was appropriate for patients. Adjuvant treatment included chemotherapy, radiotherapy, or targeted therapy. Follow-up data were gathered directly from the clinical record or telephone follow-up. CT scans were checked every 3 or 4 months to monitor recurrence and then annually after 3 years. Disease-free survival (DFS) was from the date of surgery to recurrence, or the date of final follow-up. Overall survival (OS) was measured to the date to death caused by disease or to the date of final follow-up.

Tumor-associated antigens
-------------------------

The concentrations of serum tumor biomarkers were detected by immunoenzymometric assay (Roche Diagnostics, China) within 1 week before the operation. The cut-off values of serum tumor markers were as follows: CEA 5.0 ng/ml, SCCA 1.5 ng/ml, Cyfra21-1 3.3 ng/ml, and NSE 15.2 ng/ml, using the reference values provided by the manufacturer.

Statistical analysis
--------------------

SPSS Statistics 24 (IBM Corporation, NY, USA) was used for all statistical analyses. Univariate analyses of the comparisons of baseline clinical characteristics between cohorts were carried out using the chi-squared test. Survival was conducted using Cox regression analysis. To examine differences in survival between different cohorts, the log-rank test was used. Cox proportional hazard method was applied to calculate hazard ratio (HR) and the 95% confidence intervals (CI), and the multivariate Cox method was performed using the backward selection method. In all analyses, a p-value less than 0.05 was regarded as significant.

Results
=======

Patient characteristics
-----------------------

Our study cohort included 574 lung adenocarcinoma patients who underwent partial or complete surgical resection between 2011 and 2016. As shown in [Table 1](#t1-medscimonit-25-675){ref-type="table"}, 267 (46.5%) of the patients were male and 307 (53.5%) were female. Histological diagnoses were all adenocarcinoma. The clinical stages were as follows: 288 stage I, 92 stage II, 178 stage IIIA, and 16 stage IIIB. There were 517 patients who underwent lobectomy, 36 underwent pneumonectomy, and 17 underwent wedge resection.

Of all 574 patients, 276 (48.1%) received adjuvant treatment including platinum-based adjuvant chemotherapy, postoperative radiotherapy, and anaplastic lymphoma kinase inhibitor, and the other 298 (51.9%) received no postoperative treatment. The average DFS in this cohort was 25.20 months and the average OS was 30.59 months. By the final follow-up date, 148 patients had died.

Among the ALK-positive patients, 25 (46.3%) were male and 29 (53.7%) were female ([Supplementary Table 1](#s1-medscimonit-25-675){ref-type="supplementary-material"}). The clinical stages were as follows: 27 were stage I, 11 were stage II, 13 were stage IIIA, and 3 were stage IIIB. Fifty-one patients received lobectomy, 2 received pneumonectomy, and 1 received wedge resection. The average DFS in this cohort was 18.47 months and the average OS was 25.43 months. By the last follow-up date, 7 patients had died.

Among the ALK-negative patients, 242 (46.5%) were male while 278 (53.5%) and were female ([Supplementary Table 1](#s1-medscimonit-25-675){ref-type="supplementary-material"}). The clinical stages were as follows: 261 stage I, 81 stage II, 165 stage IIIA, and 13 stage IIIB. There were 466 patients who underwent lobectomy, 34 had pneumonectomy, and 16 had wedge resection. The average DFS in this cohort was 25.90 months and the average OS was 31.12 months. By the last follow-up date, 141 patients had died.

Correlation between ALK expression and the clinicopathological characteristics
------------------------------------------------------------------------------

We further analyzed the correlation between ALK expression and clinical characteristics ([Supplementary Table 2](#s2-medscimonit-25-675){ref-type="supplementary-material"}). Univariate analysis revealed ALK expression was associated with clinicopathologic characteristics, including age (P=0.006), smoking history (P=0.008), CEA level (P≤0.001), and SCCA level (P=0.018). Multivariate logistic regression analysis of ALK expression and clinical factors showed that ALK expression was associated with age (P=0.006) and smoking history (P=0.008) ([Supplementary Table 3](#s3-medscimonit-25-675){ref-type="supplementary-material"}).

Univariate and multivariate analysis of all patients
----------------------------------------------------

Univariate analysis in all patients showed that clinical stage, surgical resection, metastasis in regional lymph node, tumor size, CEA level, and Cyfra21-1 level were associated with DFS, while OS was associated with clinical stage, surgical resection, metastasis in regional lymph node, CEA level, and Cyfra21-1 level ([Table 2](#t2-medscimonit-25-675){ref-type="table"}, [Supplementary Figures 1A, 1B](#s5-medscimonit-25-675){ref-type="supplementary-material"}, [2A, 2B](#s6-medscimonit-25-675){ref-type="supplementary-material"}). To find possible independent prognostic factors, we next conducted multivariate DFS and OS analysis in which clinical stage (P≤0.001 for DFS, P≤0.001 for OS), surgical resection (P=0.015 for DFS, P=0.011 for OS), and Cyfra21-1 (P=0.002 for DFS, P≤0.001 for OS) were identified as independent factors predicting DFS and OS ([Table 2](#t2-medscimonit-25-675){ref-type="table"}).

Univariate and multivariate analysis of ALK-positive and -negative patients
---------------------------------------------------------------------------

For ALK-positive patients, by univariate analysis, we found that DFS was related to smoking history, clinical stage, metastasis in regional lymph node, CEA level, and Cyfra21-1 level, while clinical stage, CEA, NSE, and Cyfra21-1 were correlated with OS ([Table 3](#t3-medscimonit-25-675){ref-type="table"}, [Supplementary Figure 1C, 1D](#s5-medscimonit-25-675){ref-type="supplementary-material"}, [2C, 2D](#s6-medscimonit-25-675){ref-type="supplementary-material"}). In multivariate Cox regression analysis, clinical stage (P=0.013) and Cyfra21-1 level (P=0.030) were predictive factors for DFS., while clinical stage (P=0.004) and NSE level (P=0.007) were independent prognostic factors for OS.

For ALK-negative patients, by univariate analysis, we found that DFS was related to clinical stage, surgical resection, maximum size of tumor, metastasis in regional lymph node, CEA, and Cyfra21-1, while clinical stage, surgical resection, adjuvant treatment, metastasis in regional lymph node, CEA level, and Cyfra21-1 level were correlated with OS ([Supplementary Table 4](#s4-medscimonit-25-675){ref-type="supplementary-material"}, [Supplementary Figures 1E, 1F](#s5-medscimonit-25-675){ref-type="supplementary-material"}, [2E, 2F](#s6-medscimonit-25-675){ref-type="supplementary-material"}). In multivariate Cox regression analysis, clinical stage (P≤0.001), surgical resection (P=0.013), CEA (P=0.022), and Cyfra21-1 level (P=0.008) were independent factor predicting DFS. Metastasis in regional lymph node (P≤0.001), surgical resection (P=0.013), and Cyfra21-1 level (P≤0.001) were independent prognostic factors predicting OS.

NSE analysis
------------

For all 574 patients, the average NSE level was 14.35 ng/ml. Patients were stratified into lower and higher NSE groups, one with NSE level ≤15.2 ng/ml (n=451) and another with NSE level \>15.2 ng/ml (n=120) ([Table 2](#t2-medscimonit-25-675){ref-type="table"}). The average DFS in high-NSE patients was 24.67 months as compared with 25.33 months for low-NSE patients. The average OS for high-NSE patients was 30.64 months as compared with 30.42 months for low-NSE patients. The survival analysis revealed that high serum NSE level was not relevant to OS (P=0.059) ([Figure 1A](#f1-medscimonit-25-675){ref-type="fig"}).

For ALK-positive patients, the average NSE level was 13.86 ng/ml. Patients were also stratified into lower (n=44) and higher (n=10) NSE groups ([Table 3](#t3-medscimonit-25-675){ref-type="table"}). The average DFS in high-NSE patients was 13.89 months, as compared with 19.51 months for low-NSE patients. The average OS for high-NSE patients was 19.26 months as compared with 26.83 months for low-NSE patients. The survival analysis revealed that high serum NSE level was significantly relevant to decreased OS (P=0.005) ([Figure 1B](#f1-medscimonit-25-675){ref-type="fig"}). Multivariate Cox regression analysis showed that NSE was an independent prognostic factor for OS (P=0.007).

For ALK-negative patients, the survival analysis revealed that high serum NSE level was not associated with OS (P=0.189) ([Figure 1C](#f1-medscimonit-25-675){ref-type="fig"}).

Discussion
==========

Anaplastic lymphoma kinase is a receptor protein-tyrosine kinase of the insulin receptor protein-tyrosine kinase superfamily. EML4-ALK fusion was recently reported as a neoteric targeted therapy molecular in lung cancer and has become increasingly important in the diagnosis of lung cancer. Several studies have reported that more ALK-positive cases could be seen in light- or never-smoking patients \[[@b8-medscimonit-25-675]\], type of adenocarcinoma \[[@b9-medscimonit-25-675]\], and females and young patients \[[@b10-medscimonit-25-675]\]. ALK rearrangement has also been reported to be more common in males (P=0.039) \[[@b11-medscimonit-25-675]\], but other studies reported no sex difference \[[@b8-medscimonit-25-675],[@b12-medscimonit-25-675]\]. In our study, consistent with the above-mentioned studies, ALK expression was strongly correlated with age and smoking history and was more common in never-smoking and young patients. However, no sex difference was found in our study cohort. Due to the low positive rate or other reasons, the prognostic factors in ALK-positive lung adenocarcinoma patients are unclear and no prognostic models have been developed. Therefore, it is necessary to find effective prognostic factors among these patients.

A recent study including 173 ALK-positive NSCLC patients reported that neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) were closely related to survival, and PLR was a significant prognostic factor in ALK-positive NSCLC \[[@b13-medscimonit-25-675]\]. In the study by Suzuki et al. \[[@b14-medscimonit-25-675]\], CD56^+^ was reported to be associated with poor prognosis (P=0.002) in both ALK-negative and ALK-positive subgroups. Further research is needed to better predict the prognosis of ALK-positive patients. Serum tumor makers are routinely used in examinations after admission to help guide diagnosis, classification, and treatment of these patients. To the best of our knowledge, the present study is the first to report that the level of NSE in blood is an independent prognostic factor in ALK-positive lung adenocarcinoma patients.

CEA is a kind of glycoprotein involved in programmed cell death and cell adhesion, and is normally secreted during embryonic development, but the secretion stops before birth. Its specialized sialofucosylated glycoforms serve as functional ligands that may be vital to cancer cell metastasis \[[@b15-medscimonit-25-675]\]. CEA was reported to be an unspecific serum tumor marker with abnormal expression in various solid tumors. No consensus has been reached on the prognostic value of pretreatment CEA levels in lung cancer. Tomita et al. \[[@b16-medscimonit-25-675]\] reported that CEA was a useful serum tumor marker in NSCLC and that CEA was an important prognostic factor in NSCLC patients (p\<0.0001), but other studies did not find this \[[@b5-medscimonit-25-675]\] To date, there have been no related reports on the relationship between CEA and ALK status. In our study, increased level of CEA was correlated with decreased DFS and OS in ALK-positive patients. CEA is involved in adhesion between cells and extracellular matrix, and its overexpression can inhibit cell differentiation and damage the structure of tissues. This could also partially be attributed to glycosylation of glycoproteins, which promote metastasis and invasion. The elevated level of CEA is one of the manifestations of activation of glycosylated enzymes, and other relevant molecules include AFP (α-fetoprotein) and NSE (neuron-specific enolase). Glycosylase activation leads to glycosylation of glycoproteins, which can affect ALK phosphorylation and downstream signaling \[[@b17-medscimonit-25-675]--[@b19-medscimonit-25-675]\], and thus have an effect on the prognosis of ALK-positive patients. In the present study, our cases were all adenocarcinoma patients, and CEA has already been shown to be predict poor prognosis in patients with resected lung adenocarcinomas \[[@b20-medscimonit-25-675]\].

CYFRA 21-1 is a fragment of cytokeratin (CK) 19. CK is the principal structural element of the cytoskeleton (keratin filaments) of epithelial cells, including bronchial epithelial cells. It elevated in many cell types of lung cancer, but mainly in squamous cell carcinoma \[[@b21-medscimonit-25-675]\]. It is reported that preoperative serum CYFRA 21-1 was a poor independent prognostic factor for adenocarcinoma of lung after surgery \[[@b22-medscimonit-25-675]\], which is consistent with our study. However, CYFRA 21-1 was reported to be unrelated to cancer recurrence or survival by Matsuoka et al. and Blankenburg et al., respectively \[[@b23-medscimonit-25-675],[@b24-medscimonit-25-675]\]. In our study, CYFRA 21-1 was found to be associated with decreased DFS and OS in ALK-positive patients. High serum CYFRA 21-1 level might reflect poor differentiation because multi-directional differentiation indicates tumor aggressiveness and is also considered as a poor prognostic factor in early-stage lung cancer.

NSE is a neuron-specific isoenzyme of enolase, also known as enolase-γ. The clinical significance of NSE in small cell lung cancer (SCLC) had been well accepted, since NSE is reported to be frequently elevated in patients diagnosed with SCLC \[[@b25-medscimonit-25-675]\]. However, the value of NSE in NSCLC remains unclear. In the study of Pujol et al. \[[@b7-medscimonit-25-675]\], NSE was reported to be a prognostic factor for survival. Similar results were found by other studies, including Jacot et al. \[[@b26-medscimonit-25-675]\] and Ferrigno et al. \[[@b27-medscimonit-25-675]\]. However, in the study of Reinmuth et al. \[[@b28-medscimonit-25-675]\], preoperative serum NSE level was not found to be related to prognosis. To the best of our knowledge, no research has focussed on determining the predictive role of NSE in ALK-positive lung adenocarcinoma patients. As described in our study, NSE is an independent prognostic factor for survival in ALK-positive lung adenocarcinoma patients. Since mixed element of SCLC-NSCLC may arise in a small fraction of all lung cancer cases \[[@b29-medscimonit-25-675]\] and some NSCLC patients do have an elevated NSE level, we hypothesized that the association between poor prognosis and elevated pretreatment serum NSE level in NSCLC patients might be due a co-existing neuroendocrine or small cell component in the solid tumor or tumor glucose metabolism \[[@b30-medscimonit-25-675]\]. Recently, Choi et al. \[[@b31-medscimonit-25-675]\] reported that higher glucose metabolism was found in EML4-ALK-rearranged NSCLC than in EML4-ALK-negative NSCLC patients, revealing that EML4-ALK may play a role in regulating glucose metabolism. Ma et al. \[[@b32-medscimonit-25-675]\] reported that EML4-ALK activates aerobic glycolysis, while fast ATP and a carbon source for biosynthesis require a high glycolysis rate, and thus make cancer cells replicate faster. NSE is considered a key enzyme in glycolysis and it plays an important role in aerobic glycolysis; this could partially explain how NSE affects the prognosis of ALK-positive patients. However, the adverse prognostic significance of elevated NSE was also presumed to be more malignant in lung cancers with neuroendocrine differentiation.

Adjuvant chemotherapy is not generally recommended for early-stage patients in daily clinical work. As described in our study, an elevated serum NSE level is associated with poor prognosis in ALK-positive patients. Therefore, we suggest postoperative adjuvant therapy for resected ALK-positive patients with elevated serum NSE levels.

Our study has some limitations. First, it was a single-center, retrospective investigation, so it is possible that selection bias may have affected our findings. Second, the study included an insufficient number of ALK-positive to provide strong conclusions. Nevertheless, it is the first study to show that elevated NSE level is a potential biomarker of poor prognosis for ALK-positive patients with resected lung adenocarcinoma. Further research is needed on the clinical value of NSE in prognosis.

Conclusions
===========

High serum NSE level is not relevant to decreased OS in ALK-negative patients, but NSE is an independent prognostic factor in ALK-positive patients.

Supplementary Files
===================

###### 

Patient characteristics in ALK positive(n=54) and ALK negative (n=520).

  --------------------------------------------------------
  Characteristics          ALK positive\   ALK negative\
                           n (%)           n (%)
  ------------------------ --------------- ---------------
  Age                                      

   ≤60                     41 (75.9)       295 (56.7)

   \>60                    13 (24.1)       225 (43.3)

  Sex                                      

   Male                    25 (46.3)       242 (46.5)

   Female                  29 (53.7)       278 (53.5)

  Smoking history                          

   Former/current smoker   17 (31.5)       258 (49.5)

   Never smoker            37 (68.5)       254 (48.8)

  Pathological stage                       

   I                       27 (50.0)       261 (50.2)

   II                      11 (20.4)       81 (15.6)

   IIIA                    13 (24.1)       165 (31.7)

   IIIB                    3 (5.6)         13 (2.5)

  Tumor size                               

   ≤3 cm                   36 (66.7)       312 (60)

   \>3 cm                  18 (33.3)       208 (40)

  Regional LN metastasis                   

   No                      30 (55.6)       312 (60)

  Yes                      24 (44.4)       208 (40)

  Surgical resection                       

   Pneumonectomy           2 (3.7)         34 (6.5)

   Lobectomy               51 (94.4)       466 (89.6)

   Wedge resection         1 (1.9)         16 (3.1)

  Adjuvant treatment                       

   No                      15 (27.8)       283 (54.4)

   Yes                     39 (72.2)       237 (45.6)

  CEA                                      

   ≤5.0 ng/ml              50 (92.6)       314 (60.4)

   \>5.0 ng/ml             4 (7.4)         204 (39.2)

  SCCA                                     

   ≤1.5 ng/ml              45 (83.3)       480 (92.3)

   \>1.5 ng/ml             9 (16.7)        38 (7.3)

  Cyfra21--1                               

   ≤3.3 ng/ml              36 (66.7)       346 (66.5)

   \>3.3 ng/ml             18 (33.3)       172 (33.1)

  NSE                                      

   ≤15.2 ng/ml             44 (81.5)       407 (78.3)

   \>15.2 ng/ml            10 (18.5)       110 (21.2)
  --------------------------------------------------------

LN -- lymph node; CEA -- carcinoembryonic antigen; Cyfra21-1 -- cytokeratin-19 fragments; SCCA -- squamous cell carcinoma antigen; NSE -- neuron-specific enolase.

###### 

Correlation between ALK expression and the clinicopathological characteristics.

  Characteristics          n (%)        ALK positive   ALK negative   P\*
  ------------------------ ------------ -------------- -------------- ------------
  Age                                                                 **0.006**
   ≤60                     336 (58.5)   41 (7.1)       295 (51.4)     
   \>60                    238 (41.5)   13 (2.3)       225 (39.2)     
  Sex                                                                 
   Male                    267 (46.5)   25 (4.4)       242 (42.2)     0.973
   Female                  307 (53.5)   29 (5.1)       278 (48.4)     
  Smoking history                                                     
   Former/current smoker   275 (47.9)   17 (3.0)       258 (45.6)     **0.008**
   Never smoker            291 (50.7)   37 (6.5)       254 (44.9)     
  Pathological stage                                                  
   I                       288 (50.2)   27 (4.7)       261 (45.5)     0.353
   II                      92 (16)      11 (1.9)       81 (14.1)      
   IIIA                    178 (31)     13 (2.3)       165 (28.7)     
   IIIB                    16 (2.8)     3 (0.5)        13 (2.3)       
  Tumor size                                                          
   ≤3 cm                   348 (60.6)   36 (6.3)       312 (54.4)     0.340
   \>3 cm                  226 (39.4)   18 (3.1)       208 (36.2)     
  Regional LN metastasis                                              
   No                      342 (59.6)   30 (5.2)       312 (54.4)     0.526
   Yes                     232 (40.4)   24 (4.2)       208 (36.2)     
  Surgical resection                                                  
   Pneumonectomy           36 (6.3)     2 (0.4)        34 (6.0)       0.609
   Lobectomy               517 (90.1)   51 (8.9)       466 (81.8)     
   Wedge resection         17 (3.0)     1 (0.2)        16 (2.8)       
  Adjuvant treatment                                                  
   No                      298 (51.9)   15 (2.6)       283 (49.3)     ≤**0.001**
   Yes                     276 (48.1)   39 (6.8)       237 (41.3)     
  CEA                                                                 
   ≤5.0 ng/ml              364 (63.4)   50 (8.7)       314 (54.9)     ≤**0.001**
   \>5.0 ng/ml             208 (36.2)   4 (0.7)        204 (35.7)     
  SCCA                                                                
   ≤1.5 ng/ml              525 (91.5)   45 (7.9)       480 (83.9)     **0.018**
   \>1.5 ng/ml             47 (8.2)     9 (1.6)        38 (6.6)       
  Cyfra21--1                                                          
   ≤3.3 ng/ml              382 (66.6)   36 (6.3)       346 (60.5)     0.985
   \>3.3 ng/ml             190 (33.1)   18 (3.1)       172 (30.1)     
  NSE                                                                 
   ≤15.2 ng/ml             451 (78.6)   44 (7.7)       407 (71.3)     0.636
   \>15.2 ng/ml            120 (20.9)   10 (1.8)       110 (19.3)     

LN -- lymph node; CEA -- carcinoembryonic antigen; Cyfra21-1 -- cytokeratin-19 fragments; SCCA -- squamous cell carcinoma antigen; NSE -- neuron-specific enolase.

###### 

Multivariate logistic regression analysis for ALK expression.

  Characteristics   HR (95%CI)             P\*
  ----------------- ---------------------- -----------
  Age               0.375 (0.190, 0.740)   **0.006**
  Smoking history   0.435 (0.232, 0.813)   **0.008**

HR -- hazard ratio; CI -- confidence interval.

###### 

Univariate and multivariate analyses of DFS and OS in ALK negative patients.

  Variable                 DFS   OS                                                                                                         
  ------------------------ ----- ------- ------------ ---------------------- ------------ ----- ------- ------------ ---------------------- ------------
  Age (years)                                                                                                                               
   ≤60                     295   25.85   0.646                                            295   31.59   0.694                               
   \>60                    225   25.96                                                    225   30.51                                       
  Sex                                                                                                                                       
   Male                    242   25.69   0.675                                            242   30.75   0.269                               
   Female                  278   26.09                                                    278   31.45                                       
  Smoking history                                                                                                                           
   Former/current smoker   258   25.41   0.757                                            258   30.66   0.451                               
   Never smoker            254   26.21                                                    254   31.30                                       
  Pathological stage                                                                                                                        
   I                       261   28.19   **0.026**    1.450 (1.265, 1.662)   ≤**0.001**   261   31.75   **0.005**                           0.370
   II                      81    25.69                                                    81    30.99                                       
   IIIA                    165   22.78                                                    165   30.34                                       
   IIIB                    13    20.86                                                    13    29.29                                       
  Tumor size                                                                                                                                
   ≤3 cm                   312   26.39   **0.006**                           0.583        312   30.64   0.375                               
   \>3 cm                  208   25.17                                                    208   31.84                                       
  Regional LN metastasis                                                                                                                    
   No                      312   27.81   ≤**0.001**                          0.292        312   31.46   ≤**0.001**   2.674 (1.862, 3.842)   ≤**0.001**
   Yes                     208   23.04                                                    208   30.61                                       
  Surgical resection                                                                                                                        
  Pneumonectomy            34    23.30   **0.029**    1.376 (1.070, 1.770)   **0.013**    34    30.57   **0.030**    1.482 (1.087, 2.019)   **0.013**
   Lobectomy               466   25.99                                                    466   30.96                                       
   Wedge resection         16    28.39                                                    16    35.49                                       
  Adjuvant treatment                                                                                                                        
   No                      283   25.13   0.761                                            283   29.21   **0.045**    0.440 (0.304, 0.637)   ≤**0.001**
   Yes                     237   26.82                                                    237   33.41                                       
  CEA                                                                                                                                       
   ≤5.0 ng/ml              314   27.37   ≤**0.001**   1.367 (1.046, 1.787)   **0.022**    314   31.46   **0.034**                           0.479
   \>5.0 ng/ml             204   23.65                                                    204   30.63                                       
  SCCA                                                                                                                                      
   ≤1.5 ng/ml              480   26.15   0.153                                            480   31.47   0.126                               
   \>1.5 ng/ml             38    22.82                                                    38    26.85                                       
  Cyfra21--1                                                                                                                                
   ≤3.3 ng/ml              346   26.87   **0.001**    1.421 (1.095, 1.843)   **0.008**    346   31.85   ≤**0.001**   1.839 (1.313, 2.575)   ≤**0.001**
   \>3.3 ng/ml             172   23.98                                                    172   29.68                                       
  NSE                                                                                                                                       
   ≤15.2 ng/ml             407   25.96   0.205                                            407   31.05   0.189                               
   \>15.2 ng/ml            110   25.65                                                    110   31.44                                       

LN -- lymph node; CEA -- carcinoembryonic antigen;Cyfra21-1 -- cytokeratin-19 fragments; SCCA -- squamous cell carcinoma antigen; NSE -- neuron-specific enolase; DFS -- disease-free survival; OS -- overall survival; HR -- hazard ratio; CI -- confidence interval.

###### 

Kaplan-Meier survival curves of DFS (**A**) and OS (**B**) according to CEA level in all patients. Kaplan-Meier survival curves of DFS (**C**) and OS (**D**) according to CEA level in ALK-positive patients. Kaplan-Meier survival curves of DFS (**E**) and OS (**F**) according to CEA level in ALK-negative patients.

###### 

Kaplan-Meier survival curves of DFS (**A**) and OS (**B**) according to Cyfra21-1 level in all patients. Kaplan-Meier survival curves of DFS (**C**) and OS (**D**) according to Cyfra21-1 level in ALK-positive patients. Kaplan-Meier survival curves of DFS (**E**) and OS (**F**) according to Cyfra21-1 level in ALK-negative patients.
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###### 

All patient characteristics (n=574).

  Characteristics          n (%)
  ------------------------ ------------
  Age                      
   ≤60                     336 (58.5)
   \>60                    238 (41.5)
  Sex                      
   Male                    267 (46.5)
   Female                  307 (53.5)
  Smoking history          
   Former/current smoker   275 (47.9)
   Never smoker            291 (50.7)
  Pathological stage       
   I                       288 (50.2)
   II                      92 (16)
   IIIA                    178 (31)
   IIIB                    16 (2.8)
  Tumor size               
   ≤3 cm                   348 (60.6)
   \>3 cm                  226 (39.4)
  Regional LN metastasis   
   No                      342 (59.6)
   Yes                     232 (40.4)
  Surgical resection       
   Pneumonectomy           36 (6.3)
   Lobectomy               517 (90.1)
   Wedge resection         17 (3.0)
  Adjuvant treatment       
   No                      298 (51.9)
   Yes                     276 (48.1)
  CEA                      
   ≤5.0 ng/ml              364 (63.4)
   \>5.0 ng/ml             208 (36.2)
  SCCA                     
   ≤1.5 ng/ml              525 (91.5)
   \>1.5 ng/ml             47 (8.2)
  Cyfra21--1               
   ≤3.3 ng/ml              382 (66.6)
   \>3.3 ng/ml             190 (33.1)
  NSE                      
   ≤15.2 ng/ml             451 (78.6)
   \>15.2 ng/ml            120 (20.9)

LN -- lymph node; CEA -- carcinoembryonic antigen; Cyfra21-1 -- cytokeratin-19 fragments; SCCA -- squamous cell carcinoma antigen; NSE -- neuron-specific enolase.

###### 

Univariate and multivariate analyses of DFS and OS in all patients.

  Variables                DFS   OS                                                                                                         
  ------------------------ ----- ------- ------------ ---------------------- ------------ ----- ------- ------------ ---------------------- ------------
  Age (years)                                                                                                                               
   ≤60                     336   24.93   0.893                                            336   30.57   0.918                               
   \>60                    238   25.59                                                    238   30.61                                       
  Sex                                                                                                                                       
   Male                    267   24.87   0.600                                            267   29.87   0.179                               
   Female                  307   25.49                                                    307   31.21                                       
  Smoking history                                                                                                                           
   Former/current smoker   275   24.73   0.494                                            275   30.03   0.267                               
   Never smoker            291   25.47                                                    291   30.84                                       
  Pathological stage                                                                                                                        
   I                       288   27.33   ≤**0.001**   1.479 (1.298, 1.684)   **≤0.001**   288   31.21   ≤**0.001**   1.425 (1.208, 1.682)   ≤**0.001**
   II                      92    25.54                                                    92    31.08                                       
   IIIA                    178   22.11                                                    178   29.54                                       
   IIIB                    16    19.25                                                    16    27.50                                       
  Tumor size                                                                                                                                
   ≤3 cm                   348   25.67   **0.003**                           0.601        348   30.15   0.239                               
   \>3 cm                  226   24.48                                                    226   31.26                                       
  Regional LN metastasis                                                                                                                    
   No                      342   27.12   ≤**0.001**                          0.274        342   30.94   ≤**0.001**                          0.193
   Yes                     232   22.37                                                    232   30.06                                       
  Surgical resection                                                                                                                        
   Pneumonectomy           36    22.38   **0.031**    1.354 (1.060, 1.731)   **0.015**    36    39.62   **0.019**    1.477 (1.093, 1.996)   **0.011**
   Lobectomy               517   25.29                                                    517   30.47                                       
   Wedge resection         17    27.82                                                    17    34.50                                       
  Adjuvant treatment                                                                                                                        
   No                      298   24.94   0.394                                            298   29.17   0.066                               
   Yes                     276   25.49                                                    276   32.14                                       
  CEA                                                                                                                                       
   ≤5.0 ng/ml              364   26.26   ≤**0.001**   1.308 (1.013, 1.688)   **0.039**    364   30.68   **0.005**                           0.203
   \>5.0 ng/ml             208   23.36                                                    208   30.44                                       
  SCCA                                                                                                                                      
   ≤1.5 ng/ml              525   25.55   0.096                                            525   31.04   0.164                               
   \>1.5 ng/ml             47    21.31                                                    47    25.59                                       
  Cyfra21--1                                                                                                                                
   ≤3.3 ng/ml              382   26.28   ≤**0.001**   1.482 (1.156, 1.900)   **0.002**    382   31.32   ≤**0.001**   1.818 (1.312, 2.521)   ≤**0.001**
   \>3.3 ng/ml             190   23.04                                                    190   29.14                                       
  NSE                                                                                                                                       
   ≤15.2 ng/ml             451   25.33   0.145                                            451   30.64   0.059                               
   \>15.2 ng/ml            120   24.67                                                    120   30.42                                       

LN -- lymph node; CEA -- carcinoembryonic antigen; Cyfra21-1 -- cytokeratin-19 fragments; SCCA -- squamous cell carcinoma antigen; NSE -- neuron-specific enolase; DFS -- disease-free survival; OS -- overall survival; HR -- hazard ratio; CI -- confidence interval.

###### 

Univariate and multivariate analyses of DFS and OS in ALK positive patients.

  Variables                DFS   OS                                                                                                       
  ------------------------ ----- ------- ----------- ---------------------- ----------- ---- ------- ----------- ------------------------ -----------
  Age (years)                                                                                                                             
   ≤60                     41    18.25   0125                                           41   23.24   0.370                                
   \>60                    13    19.16                                                  13   32.34                                        
  Sex                                                                                                                                     
   Male                    25    16.98   0.519                                          25   21.37   0.298                                
   Female                  29    19.75                                                  29   28.92                                        
  Smoking history                                                                                                                         
   Former/current smoker   17    14.34   **0.019**                          0.194       17   20.42   0.281                                
   Never smoker            37    20.36                                                  37   27.73                                        
   Pathological stage                                                                                                                     
   I                       27    20.16   **0.004**   17.37 (1.122, 2.687)   **0.013**   27   26.12   **0.004**   4.043 (1.551, 10.535)    **0.004**
   II                      11    21.77                                                  11   31.52                                        
   IIIA                    13    13.59                                                  13   20.16                                        
   IIIB                    3     12.27                                                  3    19.72                                        
  Tumor size                                                                                                                              
   ≤3 cm                   36    19.42   0.098                                          36   25.92   0.362                                
   \>3 cm                  18    16.57                                                  18   24.45                                        
  Regional LN metastasis                                                                                                                  
   No                      30    19.97   **0.030**                          0.997       30   25.51   0.114                                
   Yes                     24    16.59                                                  24   25.33                                        
  Surgical resection                                                                                                                      
   Pneumonectomy           2     6.73    0.521                                          2    13.50   0.303                                
   Lobectomy               51    18.92                                                  51   26.03                                        
   Wedge resection         1     18.83                                                  1    18.83                                        
  Adjuvant treatment                                                                                                                      
   No                      15    21.30   0.082                                          15   28.47   0.198                                
   Yes                     39    17.38                                                  39   24.26                                        
  CEA                                                                                                                                     
   ≤5.0 ng/ml              50    19.26   **0.023**                          0.153       50   25.80   **0.002**                            0.767
   \>5.0 ng/ml             4     8.62                                                   4    20.81                                        
  SCCA                                                                                                                                    
   ≤1.5 ng/ml              45    19.17   0.449                                          45   26.47   0.818                                
   \>1.5 ng/ml             9     14.94                                                  9    20.24                                        
  Cyfra21--1                                                                                                                              
   ≤3.3 ng/ml              36    20.66   **0.009**   2.659 (1.099, 6.433)   **0.030**   36   26.16   **0.048**                            0.231
   \>3.3 ng/ml             18    14.09                                                  18   23.96                                        
  NSE                                                                                                                                     
   ≤15.2 ng/ml             44    19.51   0.249                                          44   26.83   **0.005**   12.552 (1.977, 79.692)   **0.007**
   \>15.2 ng/ml            10    13.89                                                  10   19.26                                        

LN -- lymph node; CEA -- carcinoembryonic antigen; Cyfra21-1 -- cytokeratin-19 fragments; SCCA -- squamous cell carcinoma antigen; NSE -- neuron-specific enolase; DFS -- disease-free survival; OS -- overall survival; HR -- hazard ratio; CI -- confidence interval.
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